BioSpace News Archive

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology and inflammatory diseases, announced that it entered into an agreement with Collaborations Pharmaceuticals, Inc. to develop anti-cancer drugs utilizing artificial intelligence and machine learning techniques.

Avelo, VIVOLTA, and BLINK today announced they have won a €1.5M Eurostars grant to develop a new solution for diagnosing lower respiratory tract infections (LRTIs).

Foundation Medicine, Inc., today announced its participation in the National Cancer Institute’s (NCI) Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) initiative to test new therapy combinations in select groups of adults and children with cancer.

Vivos Therapeutics, Inc. announced that it will effect a 1-for-25 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding common stock (the “Common Stock”), effective with the opening of trading on Friday, October 27, 2023.

Mind Medicine (MindMed) Inc. announced today that it plans to host a conference call on Thursday, November 2, 2023, at 4:30 p.m. ET to provide a corporate update and review the Company’s results for the quarter ended September 30, 2023.

Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a business update.

Cybin Inc. today announced that the European Patent Office (“EP”) has granted a patent protecting Cybin’s proprietary deuterated psilocybin analog and N, N-dimethyltryptamine (“DMT”) programs.

COMPASS Pathways plc announced that Mike Falvey, Chief Financial Officer, will depart the company on November 3, 2023, to pursue other opportunities.

Intra-Cellular Therapies, Inc. today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, November 2, 2023, to provide a corporate update and discuss details of the Company’s financial results for the quarter ended September 30, 2023.

Amarin Corporation plc announced new supported and/or funded research from the landmark REDUCE-IT cardiovascular outcomes trial on the effects of VASCEPA®/VAZKEPA® in a specific patient subgroups at increased risk of a cardiovascular event has been accepted for presentation at the American Heart Association Scientific Sessions 2023, taking place November 11 – 13, 2023 in Philadelphia, PA.